MBB Public Markets I LLC Takes Position in DexCom, Inc. $DXCM

MBB Public Markets I LLC acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 4,154 shares of the medical device company's stock, valued at approximately $284,000.

• DexCom Stock: Earnings Beat and New Market Access Drive Bull Case

A number of other hedge funds and other institutional investors have also recently modified their holdings of DXCM. Golden State Wealth Management LLC lifted its position in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after acquiring an additional 264 shares during the last quarter. Private Trust Co. NA lifted its position in DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after acquiring an additional 335 shares during the last quarter. Farther Finance Advisors LLC lifted its position in DexCom by 29.3% during the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock valued at $209,000 after acquiring an additional 702 shares during the last quarter. Dynamic Advisor Solutions LLC lifted its position in DexCom by 34.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock valued at $357,000 after acquiring an additional 1,333 shares during the last quarter. Finally, Stonebridge Financial Group LLC lifted its position in DexCom by 944.5% during the first quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock valued at $220,000 after acquiring an additional 2,909 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on DXCM shares. Canaccord Genuity Group reissued a "buy" rating and set a $106.00 target price on shares of DexCom in a research report on Friday, August 1st. Argus initiated coverage on shares of DexCom in a report on Thursday, August 21st. They issued a "buy" rating and a $100.00 price target for the company. William Blair raised shares of DexCom to a "strong-buy" rating in a report on Thursday, July 31st. Mizuho raised their price target on shares of DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Finally, Morgan Stanley raised their price target on shares of DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $99.89.

• 3 New ETFs Finding Early Traction With Investors

Read Our Latest Research Report on DXCM

DexCom Price Performance

NASDAQ:DXCM opened at $76.00 on Friday. The firm has a market capitalization of $29.80 billion, a P/E ratio of 52.78, a PEG ratio of 1.59 and a beta of 1.48. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25. The company's fifty day moving average price is $81.01 and its 200-day moving average price is $78.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

• Top 3 Stocks to Watch: Options Traders Bet on Big Gains

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business's quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Transactions at DexCom

In other news, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director owned 51,121 shares in the company, valued at $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kyle Malady sold 667 shares of the firm's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,237 shares of company stock valued at $1,263,480. 0.32% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Featured Stories

• Five stocks we like better than DexCom
• What Are the U.K. Market Holidays? How to Invest and Trade
• High-Flyers Near Resistance: 3 Stocks to Watch for a Dip
• What is the S&P 500 and How It is Distinct from Other Indexes
• Seagate Technology Leads S&P 500: What’s Behind Its 120% Gain?
• Options Trading - Understanding Strike Price
• Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in DexCom Right Now?

Before you consider DexCom, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.

While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here